老年双相障碍躁狂发作:锂盐与双丙戊酸钠随机双盲对照试验
本研究为针对60岁及以上双相I型障碍躁狂、轻躁狂或混合发作患者(n=224)的随机双盲对照试验,比较锂盐与双丙戊酸钠治疗9周的耐受性与疗效。两组脱落率、镇静及达标浓度比例相似,锂盐组震颤倾向更多;锂盐在9周YMRS评分改善上优于双丙戊酸钠,但9周应答率无显著差异。
要点
- 锂盐与双丙戊酸钠在老年双相躁狂患者中耐受性均良好,脱落率与镇静无显著差异。
- 锂盐组震颤倾向更多,但两组达到目标血药浓度的比例相似。
- 锂盐在9周YMRS评分改善上优于双丙戊酸钠,但9周应答率无显著差异。
核心结论
- 锂盐与双丙戊酸钠在老年双相I型障碍躁狂发作患者中均耐受良好且有效。
- 锂盐与9周内躁狂评分更大程度降低相关。
研究设计与样本
- 随机双盲对照试验,纳入224例60岁及以上双相I型障碍躁狂、轻躁狂或混合发作的住院和门诊患者。
- 参与者随机接受锂盐(目标血清浓度0.80-0.99 mEq/L)或双丙戊酸钠(目标丙戊酸浓度80-99 μg/mL)治疗9周。
- 第3周应答不充分者接受开放标签辅助利培酮。
主要发现
- 锂盐组与双丙戊酸钠组脱落率相似:第3周分别为14%和18%,第9周分别为51%和44%。
- 两组镇静无显著差异,锂盐组震颤倾向更多。
- 锂盐组与双丙戊酸钠组达到目标浓度的比例分别为57%和56%。
- 纵向混合模型显示YMRS评分改善 favoring 锂盐(评分变化3.90;97.5% CI=1.71, 6.09)。
- 9周应答率锂盐组79%、双丙戊酸钠组73%,无显著差异;需要辅助利培酮的比例分别为17%和14%。
临床怎么用
- 对于60岁及以上双相I型障碍躁狂发作患者,锂盐和双丙戊酸钠均可作为治疗选择。
- 锂盐可能带来更大的躁狂症状改善,但需注意震颤风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Clinicians treating older patients with bipolar disorder with mood stabilizers need evidence from age-specific randomized controlled trials. The authors describe findings from a first such study of late-life mania. METHOD: The authors compared the tolerability and efficacy of lithium carbonate and divalproex in 224 inpatients and outpatients age 60 or older with bipolar I disorder who presented with a manic, hypomanic, or mixed episode. Participants were randomly assigned, under double-blind conditions, to treatment with lithium (target serum concentration, 0.80-0.99 mEq/L) or divalproex (target serum valproate concentration, 80-99 μg/mL) for 9 weeks. Participants with an inadequate response after 3 weeks received open adjunctive risperidone. The authors hypothesized that divalproex would be better tolerated and more efficacious than lithium. Tolerability was assessed based on a measure of sedation and on the proportions of participants achieving target concentrations. Efficacy was assessed with the Young Mania Rating Scale (YMRS). RESULTS: Attrition rates were similar for lithium and divalproex (14% and 18% at week 3 and 51% and 44% at week 9, respectively). The groups did not differ significantly in sedation. Participants in the lithium group tended to experience more tremor. Similar proportions of participants in the lithium and divalproex groups achieved target concentrations (57% and 56%, respectively). A longitudinal mixed model of improvement (change from baseline in YMRS score) favored lithium (change in score, 3.90; 97.5% CI=1.71, 6.09). Nine-week response rates did not differ significantly between the lithium and divalproex groups (79% and 73%, respectively). The need for adjunctive risperidone was low and similar between groups (17% and 14%, respectively). CONCLUSIONS: Both lithium and divalproex were adequately tolerated and efficacious; lithium was associated with a greater reduction in mania scores over 9 weeks.
引用
- Young RC, Mulsant BH, Sajatovic M, et al. GERI-BD: A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder. Am J Psychiatry. 2017. PMID: 29088928. doi:10.1176/appi.ajp.2017.15050657
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。